

Date: 10 November 2025

To

The Secretary

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544293

The Secretary

The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block
Bandra -Kurla Complex, Bandra (East)
Mumbai- 400 051
Scrip Symbol : SURAKSHA

Dear Sir / Ma'am,

Reg: Disclosure under Regulation 30(6) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Sub: Presentation to be made at the Analyst(s) / Investor(s) Meet/ Conference- Earnings Call

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 05 November 2025 regarding schedule of Analyst(s)/ Investor(s) Meet /Conference i.e Earnings Call on Tuesday, 11 November 2025 at 2.00 pm (IST), we hereby enclose a copy of Investor Presentation on the unaudited (standalone and consolidated) financial results of the Company for quarter and six months ended 30 September 2025.

The Investor Presentation will be exhibited at the aforesaid Earnings Call and the same will be made available on the website of the Company at www.surakshanet.com.

Please note that the schedule of the aforesaid Earnings Call is subject to change. The changes might happen due to exigencies on the part of the Company/ Analyst(s)/ Investor(s).

This may please be informed to all the concerned.

For Suraksha Diagnostic Limited

**MAMTA
JAIN**

Digitally signed by MAMTA JAIN
DN: C=IN, O=Personal, T=0287, Phone=+919831184476, Email=mamta.jain@bklabs.com
c9fe3a4631609a3118a4e77608592a3e3e12472e309cd0af
894504ff0f0d9244, PostalCode=700054, S=West Bengal,
SERIALNUMBER=11111111111111111111111111111111
ef509b868c8c4167423b58730e8817fb74e8f230c146e43fc8
b3780bdb934930, CN=MAMTA JAIN
Reason: I am the author of this document
Location: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town,
Kolkata-700 156, West Bengal, India
Date: 2025.11.10 16:49:20+05'30'
Foxit PDF Editor Version: 2024.1.0

Mamta Jain

Company Secretary & Compliance Officer

Encl: As above



Suraksha Diagnostic Limited

CIN: L85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town,
Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone:(033) 6605 9750



Suraksha
Clinic & Diagnostics

SURAKSHA DIAGNOSTIC LIMITED

Investor Presentation | Q2 & H1 FY26

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Suraksha Diagnostic Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



Suraksha
Clinic & Diagnostics

Q2 & H1 FY26 Highlights



Ritu Mittal,
Joint Managing Director & CEO

We added 5 new centres in Q2 FY26, taking our total centre count to 63 (including 2 Fetomat centres). This quarter also marked a major milestone for us with the launch of Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and molecular testing services.

Our progress with respect to market position and margins is also getting market recognition, as reflected in the recent upgrade to our credit ratings by a leading credit rating agency.

In Q2 FY26, our revenue rose by 17% YoY, reaching ₹796 million. In terms of profitability, our 42 mature centres have an EBITDA margin of 37-38% but our 21 new centres (15 centres are less than a year old) impact the overall EBITDA margin. As our new centres mature and economies of scale set in, we expect our margins to return to normal levels.

We will continue to remain prudent in our expansion journey and delivering value to our esteemed shareholders.

Business at a Glance

as of 30 September 2025

8

Labs

0.71 million

Patients Served
(H1 FY26)

4.13 million

Tests Performed
(H1 FY26)

₹ 189 million

Revenue per lab
(H1 FY26)

63

Diagnostic Centres

16

MRI Machines

27

CT Machines

₹ 2,120

Revenue per patient
(H1 FY26)

173

Collection Centres

4

NABL accredited
labs*

352

Doctors

₹ 695


EBITDA per patient
(H1 FY26)

Note: * National Accreditation Board for testing and calibration Laboratories (NABL)


Suraksha Diagnostic Limited | Investor Presentation

Key Financial Performance for Q2 FY26


Total Income (₹ million)



EBITDA (₹ million)




PAT (₹ million)



Key Financial Performance for H1 FY26

Total Income (₹ million)




EBITDA (₹ million)

36.3%
32.8%




PAT (₹ million)

14.0%
11.9%




Key Operating Metrics for H1 FY26


Number of Centres




Number of patients (million)




Number of Tests (million)



Revenue / Patient (₹)



EBITDA / Patient (₹)



Statement of Profit & Loss (Consolidated)

| Particulars (₹ million) | Q2 FY26 | Q2 FY25 | Y-o-Y | Q1 FY26 | Q-o-Q | H1 FY26 | H1 FY25 | Y-o-Y |
|---|---------------|---------------|--------|---------------|-------|-----------------|-----------------|-------|
| Revenue from Operations | 787.29 | 667.54 | | 725.86 | | 1,513.15 | 1,274.85 | |
| Other Income | 8.51 | 13.13 | | 9.06 | | 17.57 | 24.30 | |
| Total Revenue | 795.80 | 680.67 | 16.9% | 734.92 | 8.3% | 1,530.72 | 1,299.15 | 17.8% |
| Cost of Material Consumed | 89.01 | 79.31 | | 87.51 | | 176.51 | 145.68 | |
| Employee Benefit Expenses | 133.92 | 110.21 | | 127.75 | | 261.66 | 214.00 | |
| Other Expenses | 321.18 | 242.64 | | 282.01 | | 603.19 | 472.17 | |
| Impairment Loss | 2.05 | 3.43 | | -8.90 | | -6.86 | 5.02 | |
| EBITDA | 249.66 | 245.07 | 1.9% | 246.56 | 1.3% | 496.22 | 462.28 | 7.3% |
| EBITDA Margin (%) | 31.7% | 36.7% | | 34.0% | | 32.8% | 36.3% | |
| Depreciation | 101.43 | 87.49 | | 94.82 | | 196.26 | 177.42 | |
| Finance Cost | 27.76 | 21.25 | | 27.05 | | 54.81 | 43.41 | |
| Profit before Tax & Exceptional Item | 120.47 | 136.33 | -11.6% | 124.69 | -3.4% | 245.16 | 241.46 | 1.5% |
| Exceptional Item | 0.00 | 0.00 | | 0.00 | | 0.00 | 0.00 | |
| Profit before Tax | 120.47 | 136.33 | -11.6% | 124.69 | -3.4% | 245.16 | 241.46 | 1.5% |
| Profit before Tax (%) | 15.3% | 20.4% | | 17.2% | | 16.2% | 18.9% | |
| Tax | 32.19 | 34.77 | | 32.94 | | 65.13 | 63.24 | |
| Profit After Tax | 88.28 | 101.56 | -13.1% | 91.75 | -3.8% | 180.03 | 178.22 | 1.0% |
| PAT Margin (%) | 11.2% | 15.2% | | 12.6% | | 11.9% | 14.0% | |
| EPS | 1.73 | 1.94 | | 1.80 | | 3.53 | 3.43 | |

Balance Sheet (Consolidated)

| Particulars (₹ million) | H1 FY26 | FY25 |
|--|-----------------|-----------------|
| Assets | | |
| Non-current assets | | |
| Property, plant and equipment | 1,669.81 | 1,471.37 |
| Capital work-in-progress | 18.81 | 100.99 |
| Right-of-use assets | 1,042.09 | 742.90 |
| Other intangible assets | 52.31 | 15.00 |
| Intangible Assets under Development | 9.05 | 4.93 |
| Financial assets | | |
| Investments | - | 10.00 |
| Other financial assets | 150.51 | 426.91 |
| Non-current tax assets (net) | 44.08 | 16.28 |
| Other non-current assets | 81.60 | 75.33 |
| Total non-current assets | 3,068.26 | 2,863.71 |
| Current assets | | |
| Inventories | 84.46 | 80.49 |
| Financial assets | | |
| Trade receivables | 136.28 | 138.12 |
| Cash and cash equivalents | 21.07 | 22.47 |
| Bank balances other than cash and cash equivalents | 414.87 | 178.59 |
| Other financial assets | 10.10 | 25.30 |
| Other current assets | 67.44 | 26.56 |
| Total current assets | 734.22 | 471.53 |
| Total Assets | 3,802.48 | 3,335.24 |

| Particulars (₹ million) | H1 FY26 | FY25 |
|---|-----------------|-----------------|
| Equity | | |
| Equity share capital | | |
| Equity share capital | 104.16 | 104.16 |
| Instruments entirely equity in nature | - | - |
| Other equity | 2,199.75 | 2,008.24 |
| Equity attributable to owners of the parent | 2,303.91 | 2,112.40 |
| Non Controlling interest | -9.69 | (10.09) |
| Total equity | 2,294.22 | 2,102.31 |
| Liabilities | | |
| Non-current liabilities | | |
| Financial liabilities | - | - |
| Borrowings | 7.63 | 28.75 |
| Lease liabilities | 1,013.12 | 712.28 |
| Provisions | 9.39 | 10.22 |
| Deferred tax liabilities (net) | 60.33 | 54.51 |
| Total non-current liabilities | 1,090.47 | 805.77 |
| Current liabilities | | |
| Financial liabilities | | |
| Borrowings | 19.35 | 29.50 |
| Lease liabilities | 136.85 | 118.38 |
| Trade payables | - | - |
| Total outstanding dues of micro enterprises and small enterprises | 12.46 | 19.67 |
| Total outstanding dues other than above micro enterprises and small enterprises | 151.41 | 116.76 |
| Other financial liabilities | 67.59 | 107.72 |
| Other current liabilities | 28.27 | 33.80 |
| Provisions | 1.33 | 1.25 |
| Current tax liabilities (net) | 0.53 | 0.08 |
| Total current liabilities | 417.79 | 427.17 |
| Total equity and liabilities | 3,802.48 | 3,335.24 |

Statement of Cash Flows (Consolidated)

| Particulars (₹ million) | H1 FY26 | H1 FY25 |
|---|----------------|----------------|
| Profit before Tax | 245.16 | 241.46 |
| Adjustment for Non-Operating Items | 236.54 | 209.53 |
| Operating Profit before Working Capital Changes | 481.70 | 450.99 |
| Changes in Working Capital | -27.60 | -35.33 |
| Cash Generated from Operations | 454.10 | 415.66 |
| Less: Income Taxes paid | -87.17 | -42.82 |
| Net Cash from Operating Activities | 366.93 | 372.84 |
| Purchase of property, plant & equipment and other intangible assets | -234.61 | -199.09 |
| Proceeds from sale of property and equipment | 0.92 | 1.50 |
| Investment in company | - | - |
| Investments in deposits with banks | 32.02 | -72.63 |
| Acquisition of subsidiary, net of cash acquired | -32.71 | - |
| Interest received on bank deposits | 16.33 | 18.05 |
| Cash Flow from Investing Activities | -228.05 | -252.17 |
| Contribution of non-controlling interests | - | 1.00 |
| Proceeds of borrowings | - | - |
| Repayment of borrowings | -33.28 | -18.00 |
| Payment of lease liabilities | -114.93 | -103.97 |
| Others | -2.06 | -4.65 |
| Cash Flow from Financing Activities | -150.27 | -125.61 |
| Net increase/ (decrease) in Cash & Cash equivalents | -1.40 | -4.93 |
| Add: Cash and cash equivalents at the beginning of the period | 22.47 | 25.20 |
| Cash and cash equivalents at the end of the period | 21.07 | 20.27 |

EBITDA Margin (%) Breakdown by Center Age

Q1 FY26

Q2 FY26

Overall EBITDA: 34.0%

Overall EBITDA: 31.7%

**42 centres
> 2 yrs**

38.2%

37.0%

**6 centres
1 yr to 2 yrs**

6.6%

13.3%

**15 centres
< 1 yr**

-57.7%

-50.3%

EBITDA Margin (%)



Suraksha
Clinic & Diagnostics

Key Developments



ABOUT FETOMAT

- Incorporated in May 2021, Fetomat Wellness Private Limited ("Fetomat") is a network of fertility and pregnancy care clinics
- Fetomat focuses on pregnancy care, women's ultrasound scans, prenatal diagnostics, genetic counselling and medical training for doctors
- Fetomat is one of Eastern India's leading centers for fetal and maternal medicine and operated 2 centers as of 31 March 2024
- For FY24, Fetomat's turnover was ₹ 4.11 crore with an EBITDA of ₹ 0.56 crore

Key Highlights of Strategic Investment



In March 2025, the Board approved a proposal for a strategic investment in Fetomat



Upon deal completion on 09 April 2025, we held 63% stake in Fetomat



This strategic acquisition will help integrate fetal medicine expertise into our existing healthcare framework




The synergies with Fetomat will enhance innovation in fetal medical diagnostics, strengthening our industry position

About Genomics Vertical

- In July 2025, we announced the launch of Suraksha Genomics, a new vertical for advanced genetic and molecular testing services
- Suraksha Genomics offers robust infrastructure and critical capabilities across prenatal diagnostics (QF-PCR, Karyotyping, FISH, Microarray, NIPT), inherited disease analysis (including single-gene mutation detection and whole exome sequencing), pharmacogenomics, and oncology-focused molecular panels
- Focused on scaling into high-impact domains such as whole genome and metagenomic testing, AI integration and laying the groundwork for population-scale genomic screening initiatives
- Aim to contribute to national priorities such as rare disease diagnosis, newborn screening, and preventive genomics, while also expanding research and public health initiatives

Global Genetic Testing Market Size (\$ billion)





Strategy & Expansion

Suraksha
Clinic & Diagnostics

Breakdown of Launches By Center Age and Location

| | Hub Centre | Spoke Centre | Public Private Partnership (PPP) |
|----------|--------------------------------------|--|--|
| Q1 FY26 | 1 Baruipur | 4 Naihati, Shantipur, Gorabazar, Kanchrapara | 1 S. D. Hospital, Durgapur |
| Q2 FY26 | 1 Ranaghat | 3 Fetomat - 2 & Ekbalpur | 1 S. D. Hospital, Kharagpur |
| H2 FY26* | 3 Mukundapur, Dhanbad & Berhampur | 5 Shyambazar, Sonarpur, Belghoria, Krishnagar-2 & AIIR-2 | 1 Calcutta Medical College, Kolkata |

Note: * We plan to open 9 centres in H2 FY26

Centre Expansion in H1 FY26



Upcoming Centres in H2 FY26





Suraksha
Clinic & Diagnostics

Company Overview



Vision

Medium-term

We aspire to metamorphise the Company into the most reputable and cutting-edge diagnostic facility, providing precise, prompt, affordable diagnostic services that will promote early detection and long-term wellness for everybody

Long-term

Our vision is to be the most trusted and innovative diagnostic centre and set the standard for diagnostics in the future by utilising state-of-the-art technology with knowledgeable interpretation by expert professionals, accurate reporting and smooth patient experiences



Mission

To become the premier and most reliable diagnostic facility in India

To establish an accurate and cost-effective diagnostic facility

To offer our patients a better quality of reporting service

To achieve high governance standards

To have excellent financial results

To enhance the lives of people centred around Suraksha

To harness the latest advancements in diagnostic technology to provide quick, reliable results



Values


Precise diagnostic results are at the heart of Suraksha's approach

The benchmark for Suraksha's success is customer satisfaction and we aim to make diagnostic services accessible and affordable for all, supporting early detection, effective treatment and long-term health by creating a safe space for accurate health evaluations

At Suraksha, integrity in business is fundamental. We are committed to maintaining transparency and upholding the highest standards of business ethics in all our dealings


We recognise the value of time and its optimum utilisation for timely decision-making

Evolution to the Largest Integrated Diagnostic Chain in East India




Deeply Entrenched in the Vital Geography of West Bengal


- 4th most populous state in India
- Fragmented market with low penetration of chained diagnostic centers
- Accounted for 95.5% of FY25 Revenue from operations




Hub & Spoke Operating Model



.....With Demonstrated Success



Demonstrated success in Kolkata region with significant potential for future growth²




Hub centres
Offers pathology tests, basic & advanced radiology tests

Spoke centres
Offers pathology tests, basic and intermediate radiology tests


Note: 1) as of 30 September 2025; 2) Map illustrating the 'hub and spoke' model in the diagnostic centre network in Greater Kolkata, representing clusters formed by combining the hub centres and spoke centres

Well-established Operational Network - Greater Economies of Scale

Report Flow




Patients Flow



Well Equipped Clinical Infrastructure



Customer Convenience Through Value Added Services



Value Added Services enhancing customer experience and convenience

Home Collection

Allows samples to be collected from the consumers' locations, such as their homes or offices

SMS Alerts

Customers receive an SMS to download the report through email or web portal

Polyclinic Chambers

Polyclinic chambers hosting doctors providing out-patient consultation

Online Bookings

Customers can book appointments and access test reports online

Customer Centric Approach

Suraksha's Integrated System for Diagnostics

LIMS Integration

Our Laboratory Information Management System (LIMS) streamlines sample processing and report delivery. It ensures accuracy through barcoded labels and bi-directional analyser integration

RIS and PACS Workflow

The Radiology Information System (RIS) and PACS streamline imaging workflows. They integrate with registration and dispatch systems for smooth operations

Advanced Imaging Tools

PACS includes DICOM viewers with MIP, MPR, and 3D tools. These support high-quality image analysis across modalities and locations

ERP-enabled Operations

Our ERP system handles billing, inventory, procurement, and equipment use. It drives efficiency across all diagnostic centers

Error Reduction and Turnaround Time

Automation reduces errors and improves turnaround tracking. It ensures reliable and consistent service across the network

Polyclinic




160+
Chambers¹

1,000+
Doctors¹

Omnichannel medical consultation services via online and offline modes through diagnostic centres which house the polyclinic chambers

Diversified in terms of revenue from services

% of H1 FY26 Revenue



Pathology

Radiology

Other

Other includes Revenue from Doctor Consultancy and Pharmacy

Experienced Board Of Directors



Dr. Somnath Chatterjee
Chairman & Joint Managing Director

- Associated with Suraksha since incorporation; 32+ years of experience in medical and diagnostics business
- Holds bachelor's degree in medicine and surgery from University of Calcutta and is registered with West Bengal Medical Council



Ritu Mittal
Joint Managing Director & Chief Executive Officer

- Associated with Suraksha since incorporation; 28+ years of experience in the medical and diagnostics business
- Cleared the examination for a bachelor's degree in commerce from the University of Calcutta



Mr. Satish Kumar Verma
Non-Executive, Non-Independent Director

- 40+ years of experience in management
- Holds a bachelor's degree in mechanical engineering and post-graduate diploma in engineering from Punjab University



Mr. Pradip Kumar Dutta
Independent Director

- Several years of work experience. Currently, an advisor to board at Simyog Technology
- Holds B.Tech degree in electronics & electrical communication engineering from IIT, Kharagpur; a MS degree and doctorate in philosophy from the University of Maryland



Mr. Siddhartha Roy
Independent Director

- 39+ years of experience
- Holds bachelor's degree in law from Calcutta University, and also a member of the Institute of Company Secretaries of India



Mr. Dharam Chand Dharewa
Independent Director

- 30+ years of experience
- Holds bachelor's degree in commerce from G.D. Binani Mahavidyalaya, and is practicing chartered accountant since 1987



Ms. Ishani Ray
Independent Director

- 27+ years of experience in finance
- Holds bachelor's degree and master's degree in commerce from the University of Calcutta; she is an associate of the Institute of Chartered Accountants of India

Dynamic And Diverse Management Team to Deliver Next Phase of Growth



Ravindra K S
Group Chief Financial Officer

- Professional with over 20 years of extensive experience in the finance sector including the role of Group CFO at Medica Hospitals Group, Group Finance Controller at Narayana Hrudayalaya Limited and Group Manager-Finance at Aditya Birla Nuvo Limited
- He has a Bachelor's in Commerce from Kuvempu University and is a member of the Institute of Chartered Accountants of India



Mamta Jain
Company Secretary & Compliance Officer

- 9+ years of experience including with VISA International Limited and Dollar Industries Limited
- Holds a bachelor's degree in commerce from University of Calcutta, associate member of ICSI, member of the ICWAI and diploma in business administration from Symbiosis Centre for Distance Learning



Balgopal Jhunjhunwala
Regional Business Head

- 15+ years of experience
- Holds a bachelor's degree in commerce from University of Calcutta



Niren Kaul
Chief Sales Officer


- 22+ years of experience, including with Bharti Hexacom Limited and Bharti Infratel Limited
- Holds a bachelor's degree in electrical engineering from Pandit Ravishankar Shukla University, Raipur and master's degree in business administration from University of Pune



Sangeeta Chakraborty
General Manager, Operations

- 26+ years of experience
- She holds a Bachelor's degree in Arts from the University of Calcutta. She previously worked in the healthcare industry, managing inventory operations and contributing to process efficiency and supply chain coordination

Shareholding Pattern as at 30 September 2025



SOCIETE GENERALE
Securities Services

BNP PARIBAS

CITI

Nippon India
Mutual Fund
Wealth sets you free

kotak
Asset Management

ADITYA BIRLA
CAPITAL
MUTUAL FUNDS

CARNELIAN

25 YEARS Bandhan
Mutual Fund

JM Financial
MUTUAL FUND

Source: BSE

DII include Mutual Funds, AIFs and Central / State governments

FII include Foreign Direct Investments and Foreign Portfolio Investors

Others include Retail, NRIs, Bodies Corporate and others

Key Awards & Recognition

2017

Best quality in service delivery⁽¹⁾



2019

Best customer service in healthcare⁽¹⁾



2021

Business leader of the year⁽²⁾



2021

Awards & certificate of excellence⁽³⁾



2022

Outstanding diagnostic chain of
eastern India⁽⁴⁾



2023

Certificate of excellence
in exemplary trust & commitment
towards diagnostic services⁽⁵⁾



2025

Award for Talent Management
(Leadership)⁽⁶⁾



2025

Outstanding Diagnostic Chain of
Eastern India⁽⁷⁾



2025

Acknowledgment for Strides in
Genomics⁽⁴⁾




Note: 1) Awarded by ABP News; 2) by the World Leadership Congress & Awards; 3) by Zee24 Ghanta; 4) by ABP Ananda; 5) at the Health Conclave 2023 organized by Zee24 Ghanta; 6) By EILM, Kolkata; 7) by R. Bangla




Strategy & Outlook

Suraksha
Clinic & Diagnostics

Leveraging Strengths to Drive Competitive Advantage





Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets

Consolidate leading position in the core geography



Open additional diagnostic centres and increase franchisee partnerships with local entrepreneurs



Enhance the laboratory capacity and test menu by adding latest technologies



Increase home collection services



Set up more hub centres to form new clusters, and spoke centres in existing clusters

Leverage technology to elevate customer experience



Create a convenient one-stop solution through integration of digital technology, artificial intelligence and machine learning



Increase the touch points and engagement with customers through digital and technological initiatives

Expand in adjacent geographies of Eastern and North-Eastern India



Identify key locations in Eastern and North-Eastern India



Replicate the
(a) 'hub and spoke' model to unlock economies of scale
(b) polyclinic model to drive higher number of patient footfalls



Build spoke centers around the existing hub centers in Bihar, Guwahati and Meghalaya

Wider geographic reach will expand the customer base as well as improve the profitability by allowing to better leverage the infrastructure

Supplement organic growth with selective acquisitions



Selective acquisitions of and/or strategic partnerships with local diagnostic centres across Eastern and North-Eastern India



Factors while evaluating acquisition targets

- Brand recognition
- Customer base
- Technical capability and resources

Increase share of medical consultation services at diagnostic centres



Set up more polyclinics in the existing diagnostic centres, and increase the number and specialties of doctors associated



Achieve higher footfalls, tests per patient, and average revenue per patient

Engage in Business-to-business ("B2B") and corporate partnerships



Enhance revenue from the B2B segment to further diversify revenue mix and increase customer base & brand penetration



Actively seek institutional customers through referrals or internal lead-generation




Suraksha
Clinic & Diagnostics


Industry Overview

Industry: Poised For High Growth; Shifting Towards Organized Market



Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28



Organized players gaining market share from standalone labs at a steady rate



Radiology expected to grow at a relatively faster pace



Segment wise break-up of diagnostics market (FY24E)

Pathology Market (INR bn)


Radiology Market (INR bn)

Source: CRISIL Report

Note: 1) For FY20 & FY24E, Multiregional Chains account for 35-40% & 34-38% respectively of the overall Diagnostic Chains; For FY20 & FY24E, Regional Chains account for 60-65% & 62-66% respectively of the overall Diagnostic Chains


Eastern India - An “Underserved” Market With Premium Pricing

Disparity in access to accredited testing services in Eastern⁽¹⁾ India relative to population needs




NABL labs per mn population (Feb 2024)

Region has the lowest number of NABH accredited hospitals



Region wise NABH accredited hospitals

East India⁽¹⁾ market also offers premium pricing for diagnostic tests






Region-wise average diagnostic test expenditure⁽²⁾ (INR)

East India⁽¹⁾ has the highest share of population, yet the lowest share of Indian diagnostics market

East India⁽¹⁾ diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28

West Bengal diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28



Source: CRISIL Report

Note: 1) East including Northeast region is defined as: Bihar, Jharkhand, Odisha, West Bengal, Chhattisgarh; Sikkim, Arunachal Pradesh, Assam, Tripura, Mizoram, Nagaland, Manipur, Meghalaya; 2) For non-hospitalization




Suraksha
Clinic & Diagnostics


Historical Financials and Operating Metrics

Consolidated Financial Performance - Historical


Total Income (₹ million)



EBITDA (₹ million)



PAT (₹ million)




Consistent Performance Over the Years

Number of Centres

Number of Patients (million)

Number of Tests (million)




Revenue / Patient (₹)

EBITDA / Patient (₹)

ROE %

ROCE %



Statement of Profit & Loss (Consolidated)

| Particulars (₹ million) | FY25 | FY24 | FY23 | FY25 vs FY24 | FY23-25 CAGR (%) |
|---|----------------|----------------|----------------|--------------|------------------|
| Revenue from Operations | 2520.93 | 2187.09 | 1901.34 | | |
| Other Income | 38.46 | 35.51 | 35.53 | | |
| Total Revenue | 2559.39 | 2222.59 | 1936.87 | 15.2% | 15.0% |
| Cost of Material Consumed | 295.19 | 272.51 | 274.04 | | |
| Employee Benefit Expenses | 428.90 | 400.68 | 398.19 | | |
| Other Expenses | 962.55 | 811.88 | 789.85 | | |
| Impairment Loss | 21.86 | 1.34 | | | |
| EBITDA | 850.88 | 736.18 | 474.49 | 15.6% | 33.9% |
| EBITDA Margin (%) | 33.8% | 33.7% | 25.0% | | |
| Depreciation | 352.98 | 325.98 | 316.71 | | |
| Finance Cost | 83.85 | 87.88 | 90.60 | | |
| Profit before Tax & Exceptional Item | 414.05 | 322.31 | 67.48 | 28.5% | |
| Exceptional Item | - | 7.79 | - | | |
| Profit before Tax | 414.05 | 314.53 | 67.48 | 31.6% | |
| Profit before Tax (%) | 16.4% | 14.7% | 3.5% | | |
| Tax | 104.27 | 83.26 | 6.83 | | |
| Profit After Tax | 309.78 | 231.26 | 60.65 | 34.0% | 126.0% |
| PAT Margin (%) | 12.3% | 10.6% | 3.2% | | |
| EPS | 5.97 | 4.43 | 1.22 | | |

Balance Sheet (Consolidated)

| Particulars (₹ million) | FY25 | FY24 | FY23 |
|--|-----------------|-----------------|-----------------|
| Assets | | | |
| Non-current assets | | | |
| Property, plant and equipment | 1,471.37 | 1,350.50 | 1,127.89 |
| Capital work-in-progress | 100.99 | 13.13 | 23.91 |
| Right-of-use assets | 742.90 | 754.09 | 809.69 |
| Other intangible assets | 15.00 | 10.76 | 14.49 |
| Intangible Assets under Development | 4.93 | - | - |
| Financial assets | | | |
| Investments | 10.00 | - | - |
| Other financial assets | 426.91 | 84.49 | 131.56 |
| Non-current tax assets (net) | 16.28 | 18.31 | 21.41 |
| Other non-current assets | 75.33 | 46.27 | 2.49 |
| Total non-current assets | 2,863.71 | 2,277.56 | 2,131.44 |
| Current assets | | | |
| Inventories | 80.49 | 66.78 | 61.62 |
| Financial assets | | | |
| Trade receivables | 138.12 | 88.75 | 46.80 |
| Cash and cash equivalents | 22.47 | 25.20 | 21.62 |
| Bank balances other than cash and cash equivalents | 178.59 | 525.03 | 528.77 |
| Other financial assets | 25.30 | - | - |
| Other current assets | 26.56 | 18.73 | 21.70 |
| Total current assets | 471.53 | 724.49 | 680.51 |
| Total Assets | 3,335.24 | 3,002.05 | 2,811.95 |

| Particulars (₹ million) | FY25 | FY24 | FY23 |
|---|-----------------|-----------------|-----------------|
| Equity | | | |
| Equity share capital | | | |
| Equity share capital | 104.16 | 69.00 | 69.00 |
| Instruments entirely equity in nature | - | 16.29 | 16.29 |
| Other equity | 2,008.24 | 1,708.80 | 1,473.97 |
| Equity attributable to owners of the parent | 2,112.40 | 1,794.08 | 1,559.26 |
| Non Controlling interest | (10.09) | (2.62) | (4.65) |
| Total equity | 2,102.31 | 1,791.46 | 1,554.61 |
| Liabilities | | | |
| Non-current liabilities | | | |
| Financial liabilities | - | - | - |
| Borrowings | 28.75 | 51.83 | 84.36 |
| Lease liabilities | 712.28 | 703.07 | 719.28 |
| Provisions | 10.22 | 7.71 | 4.51 |
| Deferred tax liabilities (net) | 54.51 | 53.86 | 65.78 |
| Total non-current liabilities | 805.77 | 816.47 | 873.93 |
| Current liabilities | | | |
| Financial liabilities | - | - | - |
| Borrowings | 29.50 | 34.54 | 55.71 |
| Lease liabilities | 118.38 | 115.33 | 109.39 |
| Trade payables | - | - | - |
| Total outstanding dues of micro enterprises and small enterprises | 19.67 | 32.26 | 34.53 |
| Total outstanding dues other than above micro enterprises and small enterprises | 116.76 | 111.66 | 105.86 |
| Other financial liabilities | 107.72 | 77.68 | 64.71 |
| Other current liabilities | 33.80 | 17.46 | 12.41 |
| Provisions | 1.25 | - | 0.79 |
| Current tax liabilities (net) | 0.08 | 5.19 | 0.01 |
| Total current liabilities | 427.17 | 394.12 | 383.41 |
| Total equity and liabilities | 3,335.24 | 3,002.05 | 2,811.95 |

Statement of Cash Flows (Consolidated)

| Particulars (₹ million) | FY25 | FY24 | FY23 |
|---|----------------|----------------|----------------|
| Profit before Tax | 414.05 | 314.53 | 67.48 |
| Adjustment for Non-Operating Items | 428.61 | 413.29 | 397.12 |
| Operating Profit before Working Capital Changes | 842.67 | 727.82 | 464.6 |
| Changes in Working Capital | -103.26 | -36.9 | 48.29 |
| Cash Generated from Operations | 739.41 | 690.92 | 512.89 |
| Less: Income Taxes paid | -105.82 | -86.1 | -71.93 |
| Net Cash from Operating Activities | 633.59 | 604.81 | 440.96 |
| Purchase of property, plant & equipment and other intangible assets | -420.24 | -446.94 | -131.67 |
| Proceeds from sale of property and equipment | 1.41 | 17.73 | 6.61 |
| Investment in company | -10.00 | - | - |
| Investments in deposits with banks | | -413.71 | -410.51 |
| Redemption of deposits with banks | -2.60 | 461.06 | 302.25 |
| Interest received on bank deposits | 35.59 | 31.9 | 25.37 |
| Cash Flow from Investing Activities | -395.84 | -349.95 | -207.95 |
| Proceeds of borrowings | - | 5 | 20.5 |
| Repayment of borrowings | -28.11 | -58.7 | -70.7 |
| Payment of lease liabilities | -207.00 | -195.55 | -180.12 |
| Others | -5.367 | -2.05 | -12.96 |
| Cash Flow from Financing Activities | -240.48 | -251.30 | -243.28 |
| Net increase/ (decrease) in Cash & Cash equivalents | -2.73 | 3.58 | -10.27 |
| Add: Cash and cash equivalents at the beginning of the period | 25.2 | 21.62 | 31.89 |
| Cash and cash equivalents at the end of the period | 22.47 | 25.2 | 21.62 |

Company :



Suraksha Diagnostic Limited

CIN: L85110WB2005PLC102265

Email: investors@surakshanet.com

Investor Relations Advisors :



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of
MUFG Pension & Market Services

Mr. Ashish Tendulkar

ashish.tendulkar@in.mpms.mufg.com

Ms. Pooja Swami

pooja.swami@in.mpms.mufg.com

Meeting Request

Link



THANK YOU

